Iluvien 12-month results

Article

The Iluvien fluocinolone acetonide intravitreal insert (Alimera Sciences, Inc) is safe and effective in the management of diabetic macular oedema (DME) at twelve months, according to study results released by Alimera.

The Iluvien fluocinolone acetonide intravitreal insert (Alimera Sciences, Inc) is safe and effective in the management of diabetic macular oedema (DME) at twelve months, according to study results released by Alimera.

The ongoing 36-month Phase II open-label pharmacokinetic study is designed to assess the extent of systemic exposure to fluocinolone acetonide following Iluvien implantation and to assess the safety and efficacy of the insert. Of the 37 patients enrolled in the study, 20 received a dose of 0.23 µg daily, and the remaining 17 received 0.45 µg per day.

Of the patients on the high dose, 27.3% experienced a 15 letter or greater increase in best corrected visual acuity (BCVA); among low dose patients, this was 23.1%. None of the low-dose patients experienced intraocular pressure (IOP)-related adverse events; however, 23.5% of the high dose patients suffered IOP increases of ≥30 mmHg at some point throughout the study period. This was no increase over the IOP raises seen at the previous three and six month follow-up visits.

Alimera claims that these results are as expected for Iluvien at this time point. The next data will be available from the study at the 18-month time point.

Related Videos
ARVO 2024: Andrew D. Pucker, OD, PhD on measuring meibomian gland morphology with increased accuracy
 Allen Ho, MD, presented a paper on the 12 month results of a mutation agnostic optogenetic programme for patients with severe vision loss from retinitis pigmentosa
Noel Brennan, MScOptom, PhD, a clinical research fellow at Johnson and Johnson
ARVO 2024: President-elect SriniVas Sadda, MD, speaks with David Hutton of Ophthalmology Times
Elias Kahan, MD, a clinical research fellow and incoming PGY1 resident at NYU
Neda Gioia, OD, sat down to discuss a poster from this year's ARVO meeting held in Seattle, Washington
Eric Donnenfeld, MD, a corneal, cataract and refractive surgeon at Ophthalmic Consultants of Connecticut, discusses his ARVO presentation with Ophthalmology Times
John D Sheppard, MD, MSc, FACs, speaks with David Hutton of Ophthalmology Times
Paul Kayne, PhD, on assessing melanocortin receptors in the ocular space
Osamah Saeedi, MD, MS, at ARVO 2024
© 2024 MJH Life Sciences

All rights reserved.